Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance. Gilead ...

Gilead has recent experience of the hit-and ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Gilead Sciences, and Apellis Pharmaceuticals. According to TipRanks, Stringer has an average return of 7.5% ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

The Supreme Court of California is gearing up to decide an important question for the future of product liability law: Do drug manufacturers have ...

Prior to joining Gilead Canada, Paul most recently led Jazz Pharmaceuticals, where he built their Canadian organization over ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.